NUVLHIGH SIGNALREGULATORY10-K

Nuvalent announced positive pivotal Phase 2 data for zidesamtinib in June 2025 and presented results at a major cancer conference in September 2025, representing a significant regulatory milestone toward potential approval.

The completion of pivotal Phase 2 trial enrollment (435 patients) and positive data announcement marks a critical inflection point for Nuvalent's lead drug candidate. This regulatory progress validates the company's core development strategy and positions zidesamtinib for potential regulatory submissions and commercialization in ROS1-positive non-small cell lung cancer.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position reflects intensive late-stage drug development activities, with substantially higher cash reserves increasing to $261.7M (+79.7%) likely from fundraising to support pivotal trials. However, operating losses expanded meaningfully as R&D expenses grew 41% to $307M, resulting in significantly higher net losses and negative operating cash flow. The strong balance sheet provides runway for regulatory submissions and potential commercialization preparations.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+79.7%
$145.7M→$261.7M

Cash position surged 79.7% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
+68.8%
$54.0M→$91.2M

Current liabilities surged 68.8% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-63.1%
-$260.8M→-$425.4M

Net income declined 63.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-48.7%
-$185.1M→-$275.2M

Operating cash flow fell 48.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-47.8%
-$280.4M→-$414.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+41%
$217.8M→$307.0M

R&D investment increased 41% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+23.7%
$1.1B→$1.4B

Asset base grew 23.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+23%
$1.1B→$1.4B

Current assets grew 23% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+16.7%
$1.1B→$1.2B

Equity base grew 16.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 19, 2026, the registrant had 73,181,747 shares of Class A common stock, $0.0001 par value per share, outstanding and 5,435,254 shares of Class B common stock, $0.0001 par value per share, outstanding.
Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the symbols and .
Other brands, names and trademarks contained in this Annual Report are the property of their respective owners.
If we are unable to advance these product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.
Between September 2023 and June 16, 2025, 435 patients were enrolled in the Phase 2 portion of the ARROS-1 clinical trial.
In June 2025, we announced positive pivotal data for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC from the global ARROS-1 Phase 1/2 clinical trial, and in September 2025, we presented the pivotal dataset at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
The primary efficacy analysis population for this pivotal dataset consisted of 117 TKI pre-treated patients with advanced ROS1-positive NSCLC with measurable disease who received zidesamtinib at the RP2D by May 31, 2024, with duration of response (DOR) follow-up of at least 6 months available for nearly all responders.
In June 2025, we also shared preliminary data from the Phase 2 TKI-na ve cohort in the ARROS-1 clinical trial, in which enrollment is ongoing.
Encouraging preliminary data were available for 35 TKI-na ve patients with advanced ROS1-positive NSCLC treated with zidesamtinib at RP2D as of August 31, 2024.
As of June 16, 2025, a total of 104 patients had been enrolled in the ongoing TKI-na ve cohort of the ARROS-1 trial.
REMOVED
As of February 20, 2025, there were 66,162,666 shares of the registrant s Class A Common Stock, $0.0001 par value per share, outstanding and 5,435,254 shares of the registrant s Class B Common Stock, $0.0001 par value per share, outstanding.
In January 2024, we announced our OnTarget 2026 operating plan to guide efforts towards having our first potential approved product in 2026.
In September 2024, we announced achievement of all of the 2024 milestones originally laid out in the OnTarget 2026 operating plan.
At the European Society for Medical Oncology (ESMO) Congress in September 2024, we presented updated data from the Phase 1 dose-escalation portion of the ARROS-1 clinical trial based on a data cut-off date on July 1, 2024.
Data presented showed that treatment with zidesamtinib resulted in durable clinical responses in heavily pre-treated patients with ROS1-positive NSCLC, including in subgroups of patients who had likely exhausted all available therapies, including lorlatinib and/or repotrectinib, had a history of brain metastases, or had the G2032R resistance mutation.
Additionally, zidesamtinib was well-tolerated with a preliminary safety profile that was favorable and consistent with its ROS1-selective, tropomyosin receptor kinase (TRK)-sparing design.
Between September 2023 and December 31, 2024, 326 patients were enrolled in the Phase 2 portion of the ARROS-1 clinical trial.
We periodically review data from the ARROS-1 clinical trial to provide progress updates on the trial s status and to form the basis for engagement with the FDA on, among other things, the appropriate amount of information that may be sufficient to support an NDA submission.
We expect to report topline pivotal data for TKI pre-treated patients with advanced ROS1-positive NSCLC in the first half of 2025 in support of an anticipated NDA submission by mid-year 2025, with an initial target indication of TKI pre-treated patients with advanced ROS1-positive NSCLC.
We plan to continue engagement with the FDA on accelerated opportunities towards a potential line-agnostic indication supported by the ongoing TKI-na ve cohort in the Phase 2 portion of the ARROS-1 trial.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →